Primary Hyperoxaluria Management

Immediate Conservative Management

The American College of Nephrology recommends aggressive hyperhydration with 3.5-4 L/day in adults and 2-3 L/m² body surface area in children, and potassium citrate at 0.1-0.15 g/kg/day for all patients with suspected primary hyperoxaluria, while pursuing genetic testing and pyridoxine responsiveness testing in PH1 1, 2
Fluid intake targets are 3.5-4 liters daily for adults and 2-3 liters/m² body surface area for children, distributed throughout the entire 24-hour period, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2, 3
Potassium citrate should be administered orally at 0.1-0.15 g/kg/day in all patients with preserved kidney function, as suggested by the European Renal Association 1, 2, 3

The European Renal Association recommends testing pyridoxine (vitamin B6) responsiveness in all patients with PH1 immediately upon diagnosis, with a maximum dose of 5 mg/kg/day 1, 2, 3
RNA interference (RNAi) therapy is indicated for patients with PH1 who have pyridoxine non-responsive mutations or inadequate response to pyridoxine, as recommended by the American Society of Nephrology 1, 2, 4

The National Institute of Diabetes and Digestive and Kidney Diseases recommends initiating intensified hemodialysis when plasma oxalate exceeds 30 μmol/L, even if GFR would not typically warrant dialysis, using a high-flux hemodialyzer with maximal blood flow 1, 2
The American Society of Nephrology suggests increasing weekly session frequency rather than prolonging individual sessions, and targeting pre-dialysis plasma oxalate levels around 50-70 μmol/L 4

The European Renal Association recommends combined liver-kidney transplantation for patients with PH1 who do not respond to pyridoxine and have no access to RNAi therapy, as the native liver must be completely removed 1, 2, 4
Isolated kidney transplantation should be considered for patients with PH1 who are homozygous for pyridoxine-responsive mutations and demonstrate adequate response, as recommended by the American College of Nephrology 1, 2

The American Society of Nephrology recommends monitoring urinary oxalate, glycolate, citrate, calcium, and creatinine every 3-6 months during the first year, then every 6 months for 5 years in patients with preserved kidney function 3
Plasma oxalate levels should be measured every 3 months in patients with CKD Stage 4 or higher, using reference values adjusted for kidney failure, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2, 3

Over 70 % of individuals with primary hyperoxaluria progress to kidney failure, and systemic oxalosis develops when glomerular filtration rate falls below 30–40 mL/min/1.73 m². 5

Defects in hepatic glyoxylate metabolism cause excessive endogenous oxalate production that cannot be adequately cleared by the kidneys. 6, 7
Calcium‑oxalate crystals deposit within renal tubules, producing intra‑tubular and interstitial injury with chronic inflammation and obstruction. 6

When GFR declines below 30–40 mL/min/1.73 m², hepatic oxalate output exceeds renal clearance, leading to systemic deposition in bone, heart, vessels, nerves, and eyes (systemic oxalosis). 8

Type 1 (PH1) is the most common form, associated with the poorest prognosis, and results from alanine/glyoxylate aminotransferase (AGT) deficiency. 7
Types 2 and 3 (PH2, PH3) are rarer and generally have more favorable outcomes. 9
PH1 accounts for the majority of cases that advance to end‑stage renal disease. 8

Diagnosis is frequently delayed or missed until renal failure occurs, which dramatically worsens patient outcomes; clinicians should maintain a high index of suspicion in young individuals with recurrent calcium‑oxalate stones, nephrocalcinosis, or unexplained chronic kidney disease. 5

RNA‑interference (RNAi) agents are indicated for PH1 patients who are non‑responsive to pyridoxine or have an inadequate response; these therapies substantially lower endogenous oxalate production and represent a major recent therapeutic advance. 9, 10